
CONTENTS**Theme of this month : Clinical Practice of IBD —Increasingly more Drug Choices and Prospects for Further Evolution**

Editorial	<i>Jun Kato</i>	117
How to Monitor IBD and How to Change Treatment	<i>Jun Kato</i>	119
Shared Decision Making in Treatment Selection	<i>Hirono Ishikawa</i>	127
Immunological Pathogenesis of IBD and the Rationale for the Use of Molecularly Targeted Drugs	<i>Tetsuya Takagawa and Shinichiro Shinzaki</i>	134
How Should Doctors Select JAK Inhibitor or Biologic Including New Interleukin-23 Inhibitor in Ulcerative Colitis Patients with Moderately Active Phase?	<i>Masanao Nakamura, et al</i>	140
Have Treatment Strategies for Acute Severe or Severe UC Changed?	<i>Ryosuke Horio, et al</i>	147
A New Era of CD Treatment with the Advent to Anti-IL-23 Antibodies and JAK Inhibitors	<i>Satoshi Motoya, et al</i>	153
IBD-associated Serrated Lesion	<i>Masafumi Nishio, et al</i>	161
Anorectal Cancer with Crohn's Disease and Darvadstrocel for the Treatment of Perianal Fistulas in CD	<i>Akihiko Ota, et al</i>	168
Anti-integrin $\alpha v \beta 6$ Autoantibodies in Ulcerative Colitis	<i>Takeshi Kuwada, et al</i>	181
Current Status and Development of Fecal Microbiota Transplantation and Microbiome Medicine	<i>Dai Ishikawa</i>	189
Intestinal Regenerative Medicine ; Organoid Transplant for Inflammatory Bowel Disease	<i>Hiromichi Shimizu</i>	199
Artificial Intelligence for Inflammatory Bowel Disease Clinical Practice	<i>Jun Miyoshi, et al</i>	205
The Future of IBD Telemedicine and Multi-institutional Systems	<i>Yuki Hayashi, et al</i>	212

Series**How to Use the Kyoto Classification of Gastritis :**

What is the Difference between Depressive Erosion and Erosion of the Corpus?	<i>Yoshihiro Hirata</i>	219
---	-------------------------	-----

Endoscopy : Depth Diagnosis and IEE for Early Colorectal Cancer

<i>Toshiki Futakuchi, Naoto Tamai, et al</i>	224
--	-----

NIHON MEDICAL CENTER, Inc.

1-64 Kanda-jinbo-cho, Chiyoda-ku, Tokyo 101-0051, JAPAN